Content Navigation
( All
None )
| Target and Pathway |
Top |
| Target(s) |
Cannabinoid receptor 1 (CB1) |
Target Info
|
Modulator |
[2] |
| References |
Top |
| REF 1 |
ClinicalTrials.gov (NCT00239174) A Multicenter Study to Evaluate the Efficacy and Safety of of Four Doses of SR147778 in Obese Patients. U.S. National Institutes of Health.
|
| REF 2 |
Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits 9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.Br J Clin Pharmacol.2013 Jul;76(1):65-77.
|
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.
